Compare Affirm Holdings Inc (AFRM) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Affirm Holdings Inc vs Incyte Corporation — how do they compare? Affirm Holdings Inc trades at $77.35 (market cap $25.69B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Affirm Holdings Inc and Incyte Corporation are close in size by market cap, and Incyte Corporation is trading nearer its 52-week high, Affirm Holdings Inc nearer its low. Which is the better fit depends on your goals.
| AFRM | INCY | |
|---|---|---|
Market Cap | $25.69B | $24.54B |
Sector | Financials | Health |
52-Week High | $92.18 | $129.93 |
52-Week Low | $42.53 | $81.61 |
Enterprise Value | $32.30B | $20.04B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Affirm Holdings Inc
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Read more on AFRM →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
